Driving Agility in Drug Discovery: Integrating Predicted and Empirical Data

As pharmaceutical research becomes increasingly data-driven, managing the integration of computational predictions with experimental results presents a growing challenge. This webinar will examine data management methodologies for complex data sets in pharmaceutical research, as demonstrated by experts from Congruence Therapeutics.

Central to the discussion is the implementation of an integrated platform for computational drug discovery, with a focus on small molecule correctors for protein misfolding diseases. The webinar highlights how diverse data sets generated during research require structured management processes to ensure data integrity across the discovery workflow. It also examines how a centralized experimental data repository can be effectively connected with proprietary computational systems to support seamless data integration.

The technical content covers four primary methodological approaches:

• Centralized data architecture with enhanced security protocols
• Standardized integration methods for computational predictions and laboratory measurements
• Controlled data exchange procedures between internal teams and external collaborators
• Workflow automation techniques that preserve data integrity during multi-phase research cycles

These data management strategies have led to measurable gains in research efficiency over traditional approaches. The webinar outlines practical steps and implementation details for organizations looking to adopt similar data integration methods.

Experimental case studies will illustrate how these techniques are applied throughout the drug discovery process — especially during the critical transition between computational hypothesis generation and experimental validation protocols.

Register for this webinar to explore practical data management strategies for handling complex data sets across diverse research environments. Learn how to effectively align computational and experimental approaches as complementary investigative pathways in drug discovery.

Speakers

Lee Fader, PhD, VP of Chemistry, Congruence

Lee Fader is the Vice President of Chemistry at Congruence Therapeutics, specializing in small molecule drug discovery and development. Previously, he held leadership positions at Ventus Therapeutics and Inception Sciences, where he advanced early-stage therapeutic programs. His industry experience includes significant contributions at Vertex Pharmaceuticals and an extended tenure at Boehringer Ingelheim, where he progressed from Research Scientist to Principal Scientist. Lee holds a PhD from McGill University under the supervision of Dr. Youla Tsantrizos and a Bachelor of Science degree from Concordia University.

Message Presenter

Jeremy Dupaul-Chicoine, PhD, Associate Director of Biology, Congruence

Jeremy Dupaul-Chicoine, PhD, is a biologist with close to 10 years of experience in drug discovery. Currently serving as an Associate Director of Biology at Congruence Therapeutics, where he is the biology lead for the GBA1 Allosteric Modulator Program. Previously, he held various scientific roles at EnGene Inc. and was involved in the preclinical research of Detalimogene. Jeremy holds a PhD from McGill University.

Message Presenter

Maximilian Ebert, PhD, Executive Director, Computational Chemistry, Congruence

Maximilian Ebert is the Executive Director of the Computational Chemistry Group at Congruence Therapeutics, specializing in molecular dynamics and free energy calculations. Previously, he was instrumental in advancing the Molecular Operating Environment (MOE) platform at Chemical Computing Group, contributing both novel applications and business development strategies. Maximilian holds a PhD in Biochemistry from the University of Montreal, with a focus on biocatalysis and enzyme design, and a Master’s degree in Chemical Engineering from the University of Dortmund, Germany.

Message Presenter